CVAC / CureVac (CVAC) Stock Rises 25% on Positive Data for Covid-19 and Flu Vaccines

CureVac previously failed to develop a successful COVID-19 vaccine, but filed a lawsuit last year against BioNTech alleging intellectual property viol more_horizontal

CureVac NV CVAC, -3.85% said Tuesday that it has selected an mRNA flu vaccine candidate for continued clinical development, based on positive results more_horizontal

CureVac has an ongoing collaboration with GlaxoSmithKline. It just launched the first clinical study of a vaccine using CureVac's next-generation mRNA more_horizontal

The European biotech delivered some promising news from the laboratory. It has dosed its first patient in a crucial phase 1 trial of its cancer vaccin more_horizontal

The Boston-based fund has emerged as a force to be reckoned with in the world of biotech investments. more_horizontal

CureVac NV said on Friday it had filed an expanded patent infringement claim against Pfizer Inc and BioNTech over the use of mRNA technology and that more_horizontal

CureVac's CVAC, +8.44% promising Phase 1 data for flu and COVID-19 vaccine candidates is a signal to investors that its messenger RNA technology is, i more_horizontal

Shares of CureVac BV (NASDAQ: CVAC) have already almost doubled year-to-date but a UBS analyst says the stock still has a lot more room to the upside. more_horizontal